Sort
23,748 grants matching “melanoma”
Molecular Design of Filopodia, Cell's Sensory Organelles
$263,556Tatyana Svitkina · University Of Pennsylvania · R01 · FY2006 · GM
Use of Adjuvants to Improve Skin Genetic Immunizations
$263,487University Of Pittsburgh At Pittsburgh · R01 · FY2004 · CA
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy
$263,434Stanley R Riddell · Fred Hutchinson Cancer Research Center · P50 · FY2021 · CA
Animal Model for Her-2/neu Specific TCR Gene Transfer
$263,355Michael I Nishimura · Medical University Of South Carolina · R01 · FY2007 · CA
Cell-cell communication during melanoma development
$263,346Meenhard Herlyn · Wistar Institute · R01 · FY2012 · CA
Prognostic Markers for Primary Cutaneous Melanoma
$263,333Daniel Pinkel · University Of California, San Francisco · R01 · FY2006 · CA
Cell-Cell Communication During Melanoma Development
$263,309Meenhard Herlyn · Wistar Institute · R01 · FY2008 · CA
AUTOLOGOUS HAPTEN MODIFIED VACCINE FOR HUMAN CANCER
$263,279Thomas Jefferson University · R01 · FY2000 · CA
Targeting SOCS1 and RASA2 to Engineer More Potent Adoptive T Cell Therapies for Cancer Treatment.
$263,267Julia C Carnevale · University Of California, San Francisco · K08 · FY2024 · CA
Targeting SOCS1 and RASA2 to Engineer More Potent Adoptive T Cell Therapies for Cancer Treatment.
$263,267Julia C Carnevale · University Of California, San Francisco · K08 · FY2022 · CA
Targeting SOCS1 and RASA2 to Engineer More Potent Adoptive T Cell Therapies for Cancer Treatment.
$263,267Julia C Carnevale · University Of California, San Francisco · K08 · FY2023 · CA
Targeting SOCS1 and RASA2 to Engineer More Potent Adoptive T Cell Therapies for Cancer Treatment.
$263,267Julia C Carnevale · University Of California, San Francisco · K08 · FY2021 · CA
Targeting SOCS1 and RASA2 to Engineer More Potent Adoptive T Cell Therapies for Cancer Treatment.
$263,267Julia C Carnevale · University Of California, San Francisco · K08 · FY2020 · CA
Preclinical Therapeutics
$263,196Frank Patrick McCormick · University Of California, San Francisco · P30 · FY2014 · CA
Cellular Redox Control and Oxidant Signaling
$263,169A Richard Whorton · Duke University · R01 · FY2006 · HL
Development of Reagents for Labeling with At-211
$263,137Daniel Scott Wilbur · University Of Washington · R01 · FY2006 · CA
Cell-based tumor vaccines targeting CD4+ T lymphocytes
$263,130Suzanne Ostrand-Rosenberg · University Of Maryland Baltimore County · R01 · FY2011 · CA
'Arresting' bone marrow T cell sequestration in patients with GBM
$263,109Peter Fecci · Duke University · P50 · FY2020 · CA
Optimization of Melanoma Vaccines with T-Helper Epitopes
$263,096Hassane M Zarour · University Of Pittsburgh At Pittsburgh · R01 · FY2012 · CA
Optimization of Melanoma Vaccines with T-Helper Epitopes
$263,096Hassane M Zarour · University Of Pittsburgh At Pittsburgh · R01 · FY2011 · CA
Multi-strain, live biotherapeutics as adjuncts to checkpoint inhibitor therapy
$263,086Hyungsoo Kim · Sanford Burnham Prebys Medical Discovery Institute · R21 · FY2021 · CA
Inhibition of Cytochrome c-induced Caspase Activation
$263,055Sally A Kornbluth · Duke University · R01 · FY2012 · CA
Inhibition of Cytochrome c-induced Caspase Activation
$263,055Sally A Kornbluth · Duke University · R01 · FY2011 · CA
GMPS-GMPR axis melanoma progression and therapy
$263,046Mikhail Nikiforov · Wake Forest University Health Sciences · R01 · FY2018 · CA
Local blockade of IL10R on innate immune cells to mediate both innate and adaptive anti-tumor immunity
$263,034Danny Khalil · Sloan-Kettering Inst Can Research · K08 · FY2024 · CA